Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Parkinson's disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration

  • Carola, Giulia
  • Malagarriga, Daniel
  • Calatayud, Carles
  • Pons Espinal, Meritxell, 1986-
  • Blasco Agell, Lucas
  • Richaud Patin, Yvonne
  • Fernández Carasa, Irene
  • Baruffi, Valentina
  • Beltramone, Santiago
  • Molina, Emilio
  • Dell'Era, Patrizia
  • Toledo Aral, Juan J.
  • Tolosa, Eduard
  • Muotri, Alysson R.
  • García Ojalvo, Jordi
  • Soriano i Fradera, Jordi
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
A deeper understanding of early disease mechanisms occurring in Parkinson's disease (PD) is needed to reveal restorative targets. Here we report that human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (DAn) obtained from healthy individuals or patients harboring LRRK2 PD-causing mutation can create highly complex networks with evident signs of functional maturation over time. Compared to control neuronal networks, LRRK2 PD patients' networks displayed an elevated bursting behavior, in the absence of neurodegeneration. By combining functional calcium imaging, biophysical modeling, and DAn-lineage tracing, we found a decrease in DAn neurite density that triggered overall functional alterations in PD neuronal networks. Our data implicate early dysfunction as a prime focus that may contribute to the initiation of downstream degenerative pathways preceding DAn loss in PD, highlighting a potential window of opportunity for pre-symptomatic assessment of chronic degenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the MESOBRAIN project from the European Union’s Horizon 2020 research and innovation (grant agreement No. 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100, FIS2016-78507-C2-2-P, PID2019-108842GB-C21) the Spanish Ministry of Economy and Competitiveness-MINECO/AEI/FEDER, UE (BFU2016-80870-P) and the Spanish Ministry of Economy and Competitiveness- AEI/10.13039/501100011033 (PID2019-108792GB-I00), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024 and RD16/0011/0025), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. M.P.E. was partially supported by a Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia (2017 BP 00133). L.B. is the recipient of a pre-doctoral fellowship FPI (BES-2017-080579) from the Spanish Ministry of Economy and Competitiveness (MINECO). G.C. was partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Parkinson's disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration

  • Carola, Giulia
  • Malagarriga, Daniel
  • Calatayud, Carles
  • Pons Espinal, Meritxell, 1986-
  • Blasco Agell, Lucas
  • Richaud Patin, Yvonne
  • Fernández Carasa, Irene
  • Baruffi, Valentina
  • Beltramone, Santiago
  • Molina, Emilio
  • Dell'Era, Patrizia
  • Toledo Aral, Juan J.
  • Tolosa, Eduard
  • Muotri, Alysson R.
  • García Ojalvo, Jordi
  • Soriano i Fradera, Jordi
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
A deeper understanding of early disease mechanisms occurring in Parkinson's disease (PD) is needed to reveal restorative targets. Here we report that human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (DAn) obtained from healthy individuals or patients harboring LRRK2 PD-causing mutation can create highly complex networks with evident signs of functional maturation over time. Compared to control neuronal networks, LRRK2 PD patients' networks displayed an elevated bursting behavior, in the absence of neurodegeneration. By combining functional calcium imaging, biophysical modeling, and DAn-lineage tracing, we found a decrease in DAn neurite density that triggered overall functional alterations in PD neuronal networks. Our data implicate early dysfunction as a prime focus that may contribute to the initiation of downstream degenerative pathways preceding DAn loss in PD, highlighting a potential window of opportunity for pre-symptomatic assessment of chronic degenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the MESOBRAIN project from the European Union’s Horizon 2020 research and innovation (grant agreement No. 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100, FIS2016-78507-C2-2-P, PID2019-108842GB-C21) the Spanish Ministry of Economy and Competitiveness-MINECO/AEI/FEDER, UE (BFU2016-80870-P) and the Spanish Ministry of Economy and Competitiveness- AEI/10.13039/501100011033 (PID2019-108792GB-I00), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024 and RD16/0011/0025), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. M.P.E. was partially supported by a Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia (2017 BP 00133). L.B. is the recipient of a pre-doctoral fellowship FPI (BES-2017-080579) from the Spanish Ministry of Economy and Competitiveness (MINECO). G.C. was partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Atypical cyclin P regulates cancer cell stemness through activation of the WNT pathway

  • Sánchez‑Botet, Abril
  • Quandt Herrera, Eva
  • Masip, Núria
  • Escribá, Rubén
  • Novellasdemunt, Laura
  • Gasa Colom, Laura
  • Li, Vivian S. W.
  • Raya, Ángel
  • Clotet Erra, Josep
  • Ribeiro, Mariana P. C.
This work was supported by the Spanish Government, MINECO (Grant Refs: PGC2018-096597-B-I00, PGC2018-096597-B-I00 and RTI2018-095377-B-100), and Instituto de Salud Carlos IIIISCIII/FEDER (Red de Terapia Celular—TerCel RD16/0011/0024), and the Catalan Government, AGAUR (2017-SGR899), and CERCA Programme/Generalitat de Catalunya. We would like to thank Marta Pérez and Andrea Mourin for technical support, as well as Javier Jiménez and Samuel Bru for valuable scientifc discussions. The authors also wish to thank the Genomics Unit at the CRG for assistance with mRNA-seq., Purpose: Cancer stem cells represent a cancer cell subpopulation that has been found to be associated with metastasis and chemoresistance. Therefore, it is vital to identify mechanisms regulating cancer stemness. Previously, we have shown that the atypical cyclin P (CCNP), also known as CNTD2, is upregulated in lung and colorectal cancers and is associated with a worse clinical prognosis. Given that other cyclins have been implicated in pluripotency regulation, we hypothesized that CCNP may also play a role in cancer stemness. Methods: Cell line-derived spheroids, ex vivo intestinal organoid cultures and induced-pluripotent stem cells (iPSCs) were used to investigate the role of CCNP in stemness. The effects of CCNP on cancer cell stemness and the expression of pluripotency markers and ATP-binding cassette (ABC) transporters were evaluated using Western blotting and RT-qPCR assays. Cell viability was assessed using a MTT assay. The effects of CCNP on WNT targets were monitored by RNA-seq analysis. Data from publicly available web-based resources were also analyzed. Results: We found that CCNP increases spheroid formation in breast, lung and colorectal cancers, and upregulates the expression of stemness (CD44, CD133) and pluripotency (SOX2, OCT4, NANOG) markers. In addition, we found that CCNP promotes resistance to anticancer drugs and induces the expression of multidrug resistance ABC transporters. Our RNA-seq data indicate that CCNP activates the WNT pathway, and that inhibition of this pathway abrogates the increase in spheroid formation promoted by CCNP. Finally, we found that CCNP knockout decreases OCT4 expression in iPSCs, further supporting the notion that CCNP is involved in stemness regulation. Conclusion: Our results reveal CCNP as a novel player in stemness and as a potential therapeutic target in cancer., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase, Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model

  • Jung-KC, Kunwar|||0000-0002-6745-7318
  • Tristán Noguero, Alba|||0000-0002-0170-9762
  • Altankhuyag, Altanchimeg
  • Piñol Belenguer, David|||0000-0001-7490-5054
  • Prestegård, Karina S.|||0000-0003-3706-6751
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Colini Baldeschi, Arianna|||0000-0002-8638-3705
  • Sigatulina Bondarenko, Maria
  • García-Cazorla, Angels|||0000-0001-9853-688X
  • Consiglio, Antonella
  • Martinez, Aurora|||0000-0003-1643-6506
Proteostatic regulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is crucial for maintaining proper brain neurotransmitter homeostasis. Variants of the TH gene are associated with tyrosine hydroxylase deficiency (THD), a rare disorder with a wide phenotypic spectrum and variable response to treatment, which affects protein stability and may lead to accelerated degradation, loss of TH function and catecholamine deficiency. In this study, we investigated the effects of the TH cofactor tetrahydrobiopterin (BH) on the stability of TH in isolated protein and in DAn- differentiated from iPSCs from a human healthy subject, as well as from THD patients with the R233H variant in homozygosity (THDA) and R328W and T399M variants in heterozygosity (THDB). We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells. To translate this in vitro effect, we treated with BH a knock-in THD mouse model with Th variant corresponding to R233H in patients. Importantly, treatment with BH significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy). In conclusion, our study demonstrates the stabilizing effects of BH on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes. These findings highlight the therapeutic potential of BH as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Cationic Carbosilane Dendrimers Prevent Abnormal alfa-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons

  • Ortega Lopez, Paula|||0000-0003-0377-5429
  • Mata de la Mata, Francisco Javier de la|||0000-0003-0418-3935
  • Gómez Ramírez, Rafael|||0000-0001-6448-2414
  • Raya, Ángel
  • Ferrer Lorente, Raquel
  • Lozano de la Cruz, Tania
  • Fernández Carasa, Irene
  • Bryszewska, Maria
  • Milowska, Katarzyna
  • Consiglio, Antonella
Accumulation of misfolded alpha-synuclein (alpha-syn) is a hallmark of Parkinson's disease (PD) thought to play important roles in the pathophysiology of the disease. Dendritic systems, able to modulate the folding of proteins, have emerged as promising new therapeutic strategies for PD treatment. Dendrimers have been shown to be effective at inhibiting alpha-syn aggregation in cell-free systems and in cell lines. Here, we set out to investigate the effects of dendrimers on endogenous alpha-syn accumulation in disease-relevant cell types from PD patients. For this purpose, we chose cationic carbosilane dendrimers of bow-tie topology based on their performance at inhibiting alpha-syn aggregation in vitro. Dopamine neurons were differentiated from induced pluripotent stem cell (iPSC) lines generated from PD patients carrying the LRRK2(G20195) mutation, which reportedly display abnormal accumulation of alpha-syn, and from healthy individuals as controls. Treatment of PD dopamine neurons with non-cytotoxic concentrations of dendrimers was effective at preventing abnormal accumulation and aggregation of alpha-syn. Our results in a genuinely human experimental model of PD highlight the therapeutic potential of dendritic systems and open the way to developing safe and efficient therapies for delaying or even halting PD progression., European Research Council, Polish National Agency for Academic Exchange, Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Instituto de Salud Carlos III, Agencia de Gestión de Ayudas Universitarias y de Investigación, Comunidad Autónoma de Madrid, Generalitat de Catalunya